journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thoracic Oncology

journal
https://www.readbyqxmd.com/read/30414942/evaluation-of-the-prognostic-significance-of-tnm-staging-guidelines-in-lung-carcinoid-tumors
#1
J Y Yoon, K Sigel, J Martin, R Jordan, M B Beasley, C Smith, A Kaufman, J Wisnivesky, M Kang Kim
BACKGROUND: The Tumor Lymph Node and Metastasis (TNM) classification for lung cancer, originally designed for non-small cell lung carcinoma, is applied to staging of bronchopulmonary carcinoid tumors. The validity of the 8th Edition staging system for carcinoid tumors has not been assessed. In this study, we evaluated its prognostic accuracy using data from a large national population-based cancer registry. PATIENTS AND METHODS: Patients with typical and atypical bronchopulmonary carcinoids, diagnosed between 2000 and 2013, were identified from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) registry...
November 8, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30408570/neoadjuvant-crizotinib-in-resectable-locally-advanced-non-small-cell-lung-cancer-with-alk-rearrangement-a-brief-report
#2
Chao Zhang, Shao-Lei Li, Qiang Nie, Song Dong, Yang Shao, Xue-Ning Yang, Yi-Long Wu, Yue Yang, Wen-Zhao Zhong
BACKGROUND: Locally advanced non-small-cell lung cancer (NSCLC) is one of the most heterogeneous condition with multidimensional treatments involved. Neoadjuvant therapy was commonly considered as an optimal management for operable locally advanced patients. However, as targeted therapy has been widely applied in advanced NSCLC, neoadjuvant targeted therapy remains poorly explored in locally advanced disease. METHODS: We described 11 ALK (anaplastic lymphoma kinase)-positive patients with pathologically confirmed N2 NSCLC who were treated with neoadjuvant crizotinib...
November 5, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30408569/co-expression-analysis-reveals-mechanisms-underlying-the-varied-roles-of-notch1-in-non-small-cell-lung-cancer
#3
Sara L Sinicropi-Yao, Joseph M Amann, David Lopez Y Lopez, Ferdinando Cerciello, Kevin R Coombes, David P Carbone
INTRODUCTION: Notch receptor family dysregulation can be tumor promoting or suppressing depending on cellular context. Our studies shed light on the mechanistic differences that are responsible for NOTCH1's opposing roles in lung adenocarcinoma and lung squamous cell carcinoma. METHODS: We integrated transcriptional patient-derived datasets with gene co-expression analyses to elucidate mechanisms behind NOTCH1 function in subsets of non-small cell lung cancer. Differential co-expression was examined using hierarchical clustering and principal component analysis...
November 5, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30408568/a-population-based-study-of-outcomes-in-surgically-resected-t3n0-non-small-cell-lung-cancer-in-the-netherlands-defined-using-tnm-7-and-tnm-8-justification-of-changes-and-an-argument-to-incorporate-histology-in-the-staging-algorithm
#4
Hans Blaauwgeers, Ronald Damhuis, Birgit Lissenberg-Witte, Adrianus J de Langen, Suresh Senan, Erik Thunnissen
PURPOSE: To study outcomes in patients surgically staged as pT3N0 non-small cell lung cancer (NSCLC) in a population registry, comparing TNM-7 and TNM-8 staging classifications. MATERIALS AND METHODS: Details of patients who underwent surgery for a pT3N0M0 NSCLC from 2010 to 2013, based on the TNM-7 classification, were retrieved from the Netherlands Comprehensive Cancer Organization (IKNL). These were next matched with corresponding pathology data from a nationwide registry...
November 5, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30408567/peripheral-blood-dna-methylation-as-potential-biomarker-of-malignant-pleural-mesothelioma-in-asbestos-exposed-subjects
#5
Simonetta Guarrera, Clara Viberti, Giovanni Cugliari, Alessandra Allione, Elisabetta Casalone, Marta Betti, Daniela Ferrante, Anna Aspesi, Caterina Casadio, Federica Grosso, Roberta Libener, Ezio Piccolini, Dario Mirabelli, Irma Dianzani, Corrado Magnani, Giuseppe Matullo
INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive tumour strongly associated with asbestos exposure. Patients are usually diagnosed when current treatments have limited benefits, highlighting the need for non-invasive early diagnosis tests to monitor asbestos-exposed people. METHODS: We used a genome-wide methylation array to identify, in asbestos-exposed subjects, novel blood DNA methylation markers of MPM in 163 MPM cases and 137 cancer-free controls (82/68 Training Set; replication in 81/69, Test Set) sampled from the same areas...
November 5, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30391577/pet-scan-directed-chemoradiation-for-esophageal-squamous-cell-carcinoma-no-benefit-for-a-change-in-chemotherapy-in-pet-non-responders
#6
M Greally, J Chou, D Molena, V W Rusch, M S Bains, B J Park, A J Wu, K A Goodman, D P Kelsen, Y Y Janjigian, D H Ilson, G Y Ku
INTRODUCTION: Pre-operative or definitive chemoradiation is an accepted treatment for locally advanced esophageal squamous cell carcinoma (ESCC). The MUNICON study demonstrated that PET response following induction chemotherapy was predictive of outcomes in patients with gastroesophageal junction adenocarcinoma. We evaluated the predictive value of PET following induction chemotherapy in ESCC patients and assessed the impact of changing chemotherapy during radiation in PET non-responders...
October 31, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30391576/concurrent-genetic-alterations-predict-the-progression-to-target-therapy-in-egfr-mutated-advanced-non-small-cell-lung-cancer
#7
Youjin Kim, Boram Lee, Joon Ho Shim, Se-Hoon Lee, Woong-Yang Park, Yoon-La Choi, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park
INTRODUCTION: EGFR-mutant non-small cell lung cancer (NSCLC) displays diverse outcomes to tyrosine kinase inhibitor (TKI) treatment. Since co-occurring genomic alterations might describe different biological subsets of patients with this cancer, exploring co-occurring genomic alterations that impact patient`s outcome using a comprehensive gene panel is potentially important. METHODS: This retrospective cohort study was conducted with the panel-sequencing data acquired from January 2014 to May 2017, and clinical outcome data collected until February 2018...
October 31, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30391575/complete-recalcification-following-arterial-embolization-of-massive-osteolytic-bone-metastasis-from-non-small-cell-lung-cancer-nsclc
#8
Francesco Gelsomino, Giancarlo Facchini, Maria Aurelia Barbera, Giuseppe Lamberti, Stefano Brocchi, Giuseppe Rossi, Andrea Ardizzoni
No abstract text is available yet for this article.
October 31, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30391574/fulminant-myocarditis-caused-by-an-immune-checkpoint-inhibitor-a-case-report-with-pathological-findings
#9
Ryosuke Imai, Masafumi Ono, Naoki Nishimura, Koyu Suzuki, Nobuyuki Komiyama, Tomohide Tamura
No abstract text is available yet for this article.
October 31, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30368012/hybrid-capture-based-genomic-profiling-of-circulating-tumor-dna-from-patients-with-advanced-non-small-cell-lung-cancer
#10
Alexa B Schrock, Allison Welsh, Jon H Chung, Dean Pavlick, Eric H Bernicker, Benjamin C Creelan, Brady Forcier, Jeffrey S Ross, Philip J Stephens, Siraj M Ali, Ibiayi Dagogo-Jack, Alice T Shaw, Tianhong Li, Sai-Hong Ignatius Ou, Vincent A Miller
INTRODUCTION: Genomic profiling informs selection of matched targeted therapies as part of routine clinical care in non-small cell lung cancer (NSCLC). Tissue biopsy is the gold standard; however, genomic profiling of blood-derived circulating tumor DNA (ctDNA) has emerged as a minimally invasive alternative. METHODS: Hybrid capture-based genomic profiling of 62 genes was performed on blood-based ctDNA from 1,552 patients with NSCLC. RESULTS: Evidence of ctDNA was detected in 80% of samples, and of these at least one reportable genomic alteration (GA) was detected in 86% of cases...
October 24, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30368011/predicting-malignancy-risk-of-screen-detected-lung-nodules-mean-diameter-or-volume
#11
Martin Tammemagi, Alex J Ritchie, Sukhinder Atkar-Khattra, Brendan Dougherty, Calvin Sanghera, John R Mayo, Ren Yuan, Daria Manos, Annette M McWilliams, Heidi Schmidt, Michel Gingras, Sergio Pasian, Lori Stewart, Scott Tsai, Jean M Seely, Paul Burrowes, Rick Bhatia, Ehsan A Haider, Colm Boylan, Colin Jacobs, Bran van Ginneken, Ming-Sound Tsao, Stephen Lam
PURPOSE: In lung cancer screening practice using low-dose computed tomography (LDCT), diameter or volumetric measurement have been used in the management of screen detected lung nodules. The aim of this study is to compare the performance of nodule malignancy risk prediction tools using diameter or volume and between computer-aided detection (CAD) and radiologist measurements. METHODS: Multivariable logistic regression models were prepared using data from two multi-center lung cancer screening trials...
October 24, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30368010/distinct-clinicopathological-characteristics-and-prognosis-based-on-the-presence-of-ground-glass-opacity-component-in-clinical-stage-ia-lung-adenocarcinoma
#12
Aritoshi Hattori, Shunki Hirayama, Takeshi Matsunaga, Takuo Hayashi, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki
OBJECTIVES: We evaluated differences in the clinicopathological characteristics and prognosis based on the presence of ground glass opacity (GGO) components in small-sized lung adenocarcinoma. METHODS: We retrospectively investigated 634 lung adenocarcinomas classed as c-stage IA in the 8th TNM classification. Staging was defined according to the solid component size measured by thin-section computed tomography. All tumors were grouped into either a GGO or Solid group, based on the presence of a GGO component...
October 24, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30366103/prediction-modelling-using-routine-clinical-parameters-to-stratify-survival-in-malignant-pleural-mesothelioma-patients-undergoing-cytoreductive-surgery
#13
Edward Ja Harris, Steven Kao, Brian McCaughan, Takashi Nakano, Nobuyuki Kondo, Rebecca Hyland, Anna K Nowak, Nicholas H de Klerk, Fraser Jh Brims
BACKGROUND: Malignant Pleural Mesothelioma (MPM) is an uncommon cancer with a poor prognosis and heterogeneous survival. Surgery for MPM is offered in some specialist centres to highly selected patients. A previously described classification and regression tree (CART) model stratified survival in unselected MPM patients using routinely collected clinical data. This study aimed to examine the performance of this CART model on a highly selected surgical population. METHODS: Data were collected from subjects undergoing cytoreductive surgery for MPM from specialist centres in Hyõgo, Japan and Sydney, Australia between 1991 and 2016...
October 23, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30337169/learning-from-patients-reflections-on-use-of-patient-reported-outcomes-in-lung-cancer-trials
#14
Upal Basu Roy, Bellinda L King-Kallimanis, Paul G Kluetz, Wendy Selig, Andrea Ferris
No abstract text is available yet for this article.
October 15, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30336325/cribriform-subtype-is-an-independent-predictor-of-recurrence-and-survival-after-adjustment-for-the-eighth-edition-of-tnm-staging-system-in-patients-with-resected-lung-adenocarcinoma
#15
Kyuichi Kadota, Yoshio Kushida, Seiko Kagawa, Ryou Ishikawa, Emi Ibuki, Kosuke Inoue, Tetsuhiko Go, Hiroyasu Yokomise, Tomoya Ishii, Norimitsu Kadowaki, Reiji Haba
INTRODUCTION: At present, cribriform arrangements are regarded as a pattern of acinar adenocarcinoma. However, recent studies have indicated that clinical outcome for lung adenocarcinoma patients with cribriform subtype is unfavorable. To validate the prognostic significance of the cribriform pattern, we analyzed a series of 735 Japanese patients with resected lung adenocarcinoma, which was restaged according to the 8th edition of TNM staging system. METHODS: Tumors were classified in accordance with the 2015 WHO classification of lung carcinomas...
October 15, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30336324/association-of-early-palliative-care-with-chemotherapy-intensity-in-patients-with-advanced-stage-lung-cancer-a-national-cohort-study
#16
A Lammers, C G Slatore, E K Fromme, K Vranas, D R Sullivan
No abstract text is available yet for this article.
October 15, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30391573/compliance-and-outcome-of-elderly-patients-treated-in-the-concurrent-once-daily-versus-twice-daily-radiotherapy-convert-trial
#17
Marianna Christodoulou, Fiona Blackhall, Hitesh Mistry, Ahmet Leylek, Joost Knegjens, Vincent Remouchamps, Isabelle Martel-Lafay, Nuria Farré, Matjaz Zwitter, Delphine Lerouge, Nicolas Pourel, Henri Janicot, Arnaud Scherpereel, Caroline Tissing-Tan, Karin Peignaux, Xavier Geets, Krzysztof Konopa, Corinne Faivre-Finn
INTRODUCTION: There is a lack of data on the efficacy and safety of concurrent chemo-radiotherapy in elderly, limited-stage, patients with small cell lung cancer. METHODS: We compared outcomes of patients aged ≥70 years vs. younger patients within the Concurrent ONce-daily VErsus twice-daily RadioTherapy (CONVERT) trial. Patients were randomised to receive 45Gy/30 twice-daily fractions/3 weeks or 66Gy/33 once-daily fractions/6.5 weeks concurrently with platinum-based chemotherapy...
October 11, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30316012/neoantigenic-potential-of-complex-chromosomal-rearrangements-in-mesothelioma
#18
Aaron S Mansfield, Tobias Peikert, James B Smadbeck, Julia B M Udell, Enrique Garcia-Rivera, Laura Elsbernd, Courtney L Erskine, Virginia P Van Keulen, Farhad Kosari, Stephen J Murphy, Hongzheng Ren, Vishnu V Serla, Janet L Schaefer Klein, Giannoula Karagouga, Faye R Harris, Carlos Sosa, Sarah H Johnson, Wendy Nevala, Svetomir N Markovic, Aaron O Bungum, Eric S Edell, Haidong Dong, John C Cheville, Marie Christine Aubry, Jin Jen, George Vasmatzis
INTRODUCTION: Malignant pleural mesothelioma is a disease primarily associated with exposure to the carcinogen asbestos. Whereas other carcinogen-related tumors are associated with a high tumor mutation burden, mesothelioma is not. We sought to resolve this discrepancy. MATERIAL AND METHODS: We used mate-pair (n=22), RNA (n=28) and T cell receptor sequencing along with in silico predictions and immunologic assays to understand how structural variants of chromosomes affect the transcriptome...
October 10, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30316011/demographics-safety-and-quality-and-prognostic-information-in-both-the-seventh-and-eighth-editions-of-the-tnm-classification-in-18-973-surgical-cases-of-the-japanese-joint-committee-of-lung-cancer-registry-database-in-2010
#19
Jiro Okami, Yasushi Shintani, Meinoshin Okumura, Hiroyuki Ito, Takashi Ohtsuka, Shinichi Toyooka, Takeshi Mori, Shun-Ichi Watanabe, Hiroshi Date, Kohei Yokoi, Hisao Asamura, Takeshi Nagayasu, Etsuo Miyaoka, Ichiro Yoshino
INTRODUCTION: The Japanese Joint Committee of Lung Cancer Registry (JJCLCR) performed the fourth nationwide registry study of surgical cases. Demographics, safety and quality, prognostic information, and correlations between the 7th and the 8th editions of the TNM classification were investigated. The principal results were compared with previous JJCLCR studies. METHODS: The clinicopathologic profiles, staging, and prognosis of patients who underwent surgery for primary lung cancer in 2010 were retrospectively collected in 2016 and analyzed...
October 10, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30316010/third-line-nivolumab-monotherapy-in-recurrent-small-cell-lung-cancer-checkmate-032
#20
Neal Ready, Anna F Farago, Filippo de Braud, Akin Atmaca, Matthew D Hellmann, Jeffrey G Schneider, David R Spigel, Victor Moreno, Ian Chau, Christine L Hann, Joseph Paul Eder, Nicola L Steele, Anne Pieters, Justin Fairchild, Scott J Antonia
INTRODUCTION: For patients with recurrent small cell lung cancer (SCLC), topotecan remains the only FDA-approved or EMA-approved second-line treatment, and outcomes are poor. CheckMate 032 is a phase 1/2, multicenter, open-label study of nivolumab or nivolumab plus ipilimumab in SCLC or other advanced/metastatic solid tumors previously treated with ≥1 platinum-based chemotherapies. We report results of third- or later-line (3L+) nivolumab monotherapy treatment in SCLC. METHODS: In this analysis, patients with limited-stage or extensive-stage SCLC and disease progression after ≥2 chemotherapy regimens received nivolumab monotherapy 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity...
October 10, 2018: Journal of Thoracic Oncology
journal
journal
41363
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"